Oxigene Receives Fast Track Designation From U.S. FDA for CA4P
30 mars 2016 08h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Reports 2015 Financial Results
28 mars 2016 08h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
25 mars 2016 08h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Appoints Dr. Simon Pedder to Board of Directors
24 mars 2016 08h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update
03 févr. 2016 09h00 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
06 janv. 2016 08h00 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia
17 déc. 2015 15h00 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Reports Third Quarter 2015 Financial Results
10 nov. 2015 16h15 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
05 nov. 2015 16h15 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia
21 oct. 2015 16h15 HE
|
Mateon Therapeutics
First patient dosed in OXiGENE-sponsored expansion of investigator trial
Phase 1b/2 dose-escalation study of OXi4503 as a single agent and in combination with cytarabine
SOUTH SAN...